Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
2017 · Journal of Clinical Oncology · 580 citations
https://doi.org/10.1200/jco.2016.71.5904
H
Howard West
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
297
Papers
12.2K
Citations
42
h-index
116
i10-index
Howard West is an academic researcher. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Lung Cancer Diagnosis and Treatment. The author has an h-index of 42, co-authored 253 publications.
ORCID: 0000-0003-3257-0086Papers by this author
worksAtezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
2020 · Journal of Thoracic Oncology · 430 citations
https://doi.org/10.1016/j.jtho.2020.11.025
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
2017 · Cancer Chemotherapy and Pharmacology · 38 citations
https://doi.org/10.1007/s00280-017-3283-z
Adolescents and Young Adults With Cancer
2023 · JAMA Oncology · 29 citations
https://doi.org/10.1001/jamaoncol.2022.6132
Promoter methylation of glutathione S‒transferase π1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma and its correlation with DNA methyltransferase 1 expression
2010 · Cancer · 3 citations
https://doi.org/10.1002/cncr.24983
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat